The Impact of SETBP1 Mutations in Neurological Diseases and Cancer

Overview

Journal Genes Cells

Specialties Cell Biology
Molecular Biology

Date 2023 Jul 25

PMID 37489294

Authors

Naoki Kohyanagi

Takashi Ohama

Affiliations

Soon will be listed here.

Abstract

SE translocation (SET) is a cancer-promoting factor whose expression is upregulated in many cancers. High SET expression positively correlates with a poor cancer prognosis. SETBP1 (SET-binding protein 1/SEB/MRD29), identified as SET-binding protein, is the causative gene of Schinzel-Giedion syndrome, which is characterized by severe intellectual disability and a distorted facial appearance. Mutations in these genetic regions are also observed in some blood cancers, such as myelodysplastic syndromes, and are associated with a poor prognosis. However, the physiological role of SETBP1 and the molecular mechanisms by which the mutations lead to disease progression have not yet been fully elucidated. In this review, we will describe the current epidemiological data on SETBP1 mutations and shed light on the current knowledge about the SET-dependent and -independent functions of SETBP1.

Citing Articles

Mutational disparities in colorectal cancers of White Americans, Alabama African Americans, And Oklahoma American Indians.

Yamada H, Rout M, Xu C, ONeill P, Afaq F, Morris K NPJ Precis Oncol. 2024; 8(1):288.

PMID: 39715885 PMC: 11666716. DOI: 10.1038/s41698-024-00782-9.

Epigenetics in rare neurological diseases.

Roberts C, Arezoumand K, Kadar Shahib A, Davie J, Rastegar M Front Cell Dev Biol. 2024; 12:1413248.

PMID: 39108836 PMC: 11300358. DOI: 10.3389/fcell.2024.1413248.

1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit.

Nahalka J Int J Mol Sci. 2024; 25(8).

PMID: 38674024 PMC: 11049929. DOI: 10.3390/ijms25084440.

The landscape of SETBP1 gene expression and transcription factor activity across human tissues.

Whitlock J, Wilk E, Howton T, Clark A, Lasseigne B PLoS One. 2024; 19(1):e0296328.

PMID: 38165902 PMC: 10760659. DOI: 10.1371/journal.pone.0296328.

The landscape of gene expression and transcription factor activity across human tissues.

Whitlock J, Wilk E, Howton T, Clark A, Lasseigne B bioRxiv. 2023; .

PMID: 37873221 PMC: 10592643. DOI: 10.1101/2023.08.08.551337.

References

Minakuchi M, Kakazu N, Abe T, Copeland T, Ueda K, Adachi Y . Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem. 2001; 268(5):1340-51. DOI: 10.1046/j.1432-1327.2001.02000.x. View

Takeuchi A, Okamoto N, Fujinaga S, Morita H, Shimizu J, Akiyama T . Progressive brain atrophy in Schinzel-Giedion syndrome with a SETBP1 mutation. Eur J Med Genet. 2015; 58(8):369-71. DOI: 10.1016/j.ejmg.2015.05.006. View

Suphapeetiporn K, Srichomthong C, Shotelersuk V . SETBP1 mutations in two Thai patients with Schinzel-Giedion syndrome. Clin Genet. 2011; 79(4):391-3. DOI: 10.1111/j.1399-0004.2010.01552.x. View

Coudray N, Ocampo P, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D . Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018; 24(10):1559-1567. PMC: 9847512. DOI: 10.1038/s41591-018-0177-5. View

Park S, So M, Cho M, Kim D, Huh J . Coexistence of Primary Myelofibrosis and Paroxysmal Nocturnal Hemoglobinuria Clone with V617F, and Mutations: A Case Report and Brief Review of Literature. Diagnostics (Basel). 2021; 11(9). PMC: 8466901. DOI: 10.3390/diagnostics11091644. View

Carratt S, Kong G, Curtiss B, Schonrock Z, Maloney L, Maniaci B . Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms. Blood. 2022; 140(6):644-658. PMC: 9373012. DOI: 10.1182/blood.2021014777. View

Carratt S, Braun T, Coblentz C, Schonrock Z, Callahan R, Curtiss B . Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia. 2021; 35(12):3594-3599. PMC: 8595361. DOI: 10.1038/s41375-021-01278-2. View

Saika M, Inoue D, Nagase R, Sato N, Tsuchiya A, Yabushita T . ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation. Sci Rep. 2018; 8(1):15873. PMC: 6203835. DOI: 10.1038/s41598-018-33881-2. View

Mori N, Ohwashi-Miyazaki M, Yoshinaga K, Ogasawara T, Marshall S, Shiseki M . Genetic alterations in patients with chronic leucocytosis and persistent thrombocytosis. J Genet. 2022; 101. View

10.

Nie Y, Shao L, Zhang H, He C, Li H, Zou J . Mutational landscape of chronic myelomonocytic leukemia in Chinese patients. Exp Hematol Oncol. 2022; 11(1):32. PMC: 9128105. DOI: 10.1186/s40164-022-00284-z. View

11.

Kim J, Lee K, Seol J, Yu K, Chakravarti D, Seo S . Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity. Nucleic Acids Res. 2011; 40(1):75-87. PMC: 3245910. DOI: 10.1093/nar/gkr614. View

12.

Leone M, Palumbo P, Palumbo O, Di Muro E, Chetta M, Laforgia N . The recurrent SETBP1 c.2608G > A, p.(Gly870Ser) variant in a patient with Schinzel-Giedion syndrome: an illustrative case of the utility of whole exome sequencing in a critically ill neonate. Ital J Pediatr. 2020; 46(1):74. PMC: 7254667. DOI: 10.1186/s13052-020-00839-y. View

13.

Karantanos T, Gondek L, Varadhan R, Moliterno A, DeZern A, Jones R . Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Br J Haematol. 2021; 193(6):1142-1150. PMC: 8217263. DOI: 10.1111/bjh.17534. View

14.

Volk A, Conboy E, Wical B, Patterson M, Kirmani S . Whole-Exome Sequencing in the Clinic: Lessons from Six Consecutive Cases from the Clinician's Perspective. Mol Syndromol. 2015; 6(1):23-31. PMC: 4369115. DOI: 10.1159/000371598. View

15.

Anil V, Gosal H, Kaur H, Chakwop Ngassa H, Elmenawi K, Mohammed L . Chronic Neutrophilic Leukemia: A Literature Review of the Rare Myeloproliferative Pathology. Cureus. 2021; 13(6):e15433. PMC: 8253489. DOI: 10.7759/cureus.15433. View

16.

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

17.

Touge H, Fujinaga T, Okuda M, Aoshi H . Schinzel-Giedion syndrome. Int J Urol. 2001; 8(5):237-41. DOI: 10.1046/j.1442-2042.2001.00291.x. View

18.

Kim H, Lee J, Kang D, Yu H, Kim Y, Kang H . Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. Br J Haematol. 2021; 195(5):748-756. DOI: 10.1111/bjh.17861. View

19.

Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Minervini A . SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia. J Hematol Oncol. 2012; 5:48. PMC: 3470981. DOI: 10.1186/1756-8722-5-48. View

20.

Lucas C, Scott L, Carmell N, Holcroft A, Hills R, Burnett A . CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Adv. 2018; 2(9):964-968. PMC: 5941996. DOI: 10.1182/bloodadvances.2017013615. View